Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul R Hutson

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Toxicology Reports|October 4, 2023
Pharmacokinetic analysis of acute and dietary exposure to piperonyl butoxide in the mouseAlyssa E Jenkins, Cameron O Scarlett, Tyler G Beames, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|April 16, 2008
Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouseRobert J Lipinski, Paul R Hutson, Paul W Hannam, et al.
Journal of Psychopharmacology (Oxford, England)|June 28, 2018
High dose psilocybin is associated with positive subjective effects in healthy volunteersChristopher R Nicholas, Kelsey M Henriquez, Michele C Gassman, et al.
Cancer Research Communications|August 12, 2025
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid TumorsKenneth B DeSantes, Kimberly A McDowell, Paul M Sondel, et al.
Clinical Pharmacokinetics|March 30, 2017
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy AdultsRandall T Brown, Christopher R Nicholas, Nicholas V Cozzi, et al.
Translational Psychiatry|February 13, 2026
Electrophysiological effects of psilocybin co-administered with midazolamMichael H Sutherland, Christopher R Nicholas, Richard C Lennertz, et al.
Clinical Pharmacology and Therapeutics|May 16, 2002
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumorsDiane R Mould, Nicholas H G Holford, Jan H M Schellens, et al.
Translational Psychiatry|September 12, 2024
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experienceChristopher R Nicholas, Matthew I Banks, Richard C Lennertz, et al.
JAMA|August 31, 2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical TrialCharles L Raison, Gerard Sanacora, Joshua Woolley, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Toxicology Reports|October 4, 2023
Pharmacokinetic analysis of acute and dietary exposure to piperonyl butoxide in the mouseAlyssa E Jenkins, Cameron O Scarlett, Tyler G Beames, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|April 16, 2008
Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouseRobert J Lipinski, Paul R Hutson, Paul W Hannam, et al.
Journal of Psychopharmacology (Oxford, England)|June 28, 2018
High dose psilocybin is associated with positive subjective effects in healthy volunteersChristopher R Nicholas, Kelsey M Henriquez, Michele C Gassman, et al.
Cancer Research Communications|August 12, 2025
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid TumorsKenneth B DeSantes, Kimberly A McDowell, Paul M Sondel, et al.
Clinical Pharmacokinetics|March 30, 2017
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy AdultsRandall T Brown, Christopher R Nicholas, Nicholas V Cozzi, et al.
Translational Psychiatry|February 13, 2026
Electrophysiological effects of psilocybin co-administered with midazolamMichael H Sutherland, Christopher R Nicholas, Richard C Lennertz, et al.
Clinical Pharmacology and Therapeutics|May 16, 2002
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumorsDiane R Mould, Nicholas H G Holford, Jan H M Schellens, et al.
Translational Psychiatry|September 12, 2024
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experienceChristopher R Nicholas, Matthew I Banks, Richard C Lennertz, et al.
JAMA|August 31, 2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical TrialCharles L Raison, Gerard Sanacora, Joshua Woolley, et al.
Pageof 3